Biography

Dr. Srinivasan is a Staff Clinician in the Urologic Oncology Branch, National Cancer Institute (NCI). He obtained his M.D., from the Bangalore Medical College in India and completed his Ph.D., in biomedical sciences at the University of Texas MD Anderson Cancer Center in Houston. He came to NCI in 1999 after completing his Internal Medicine Residency training at the University of Texas Health Science Center-Houston, to pursue a fellowship in Medical Oncology/Hematology. After completing his fellowship, he joined the Urologic Oncology Branch, where he is developing treatment strategies and clinical trials for patients with both hereditary and non-hereditary forms of kidney cancer. He is currently investigating a variety of newer 'targeted' agents in clear cell and papillary kidney cancer, as well as hereditary kidney cancer syndromes such as von Hippel-Lindau, hereditary leiomyomatosis and renal cell cancer and hereditary papillary renal cell cancer (HPRC). 

Research Intrest

kidney cancer 

List of Publications
Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, et al. (2013) Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J. Clin. Oncol. 31: 181-6.
Linehan WM, Srinivasan R, Garcia JA (2013) Non-clear cell renal cancer: disease-based management and opportunities for targeted therapeutic approaches. Semin. Oncol. 40: 511-20.
Liu NW, Sanford T, Srinivasan R, Liu JL, Khurana K, et al. (2013) Impact of ischemia and procurement conditions on gene expression in renal cell carcinoma. Clin. Cancer Res. 19: 42-9.
Shuch B, Linehan WM, Srinivasan R (2013) Aerobic glycolysis: a novel target in kidney cancer. Expert Rev Anticancer Ther. 13: 711-9.
Shuch B, Vourganti S, Ricketts CJ, Middleton L, Peterson J, et al. (2014) Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J. Clin. Oncol. 32: 431-7.